@article{open2452,
          volume = {90},
           month = {October},
          author = {Somendu K Roy and Neela Kumari and Sonika Pahwa and Udai C Agrahari and Kamlesh K Bhutani and Sanjay M Jachak and Hemraj Nandanwar},
            note = {Copyright of this article belongs to Elsevier Science.},
           title = {NorA efflux pump inhibitory activity of coumarins from Mesua ferrea.},
       publisher = {Elsevier Science},
         journal = {Fitoterapia},
           pages = {140--50},
            year = {2013},
        keywords = {Clinical strain; Coumarins; Mesua ferrea; NorA-pump inhibitor; Staphylococcus aureus},
             url = {http://crdd.osdd.net/open/2452/},
        abstract = {The purpose of this investigation was to study the modulator and efflux pump inhibitor activity of coumarins isolated from Mesua ferrea against clinical strains as well as NorA-over expressed strain of Staphylococcus aureus 1199B. Seven coumarins were tested for modulator activity using ethidium bromide (EtBr) as a substrate. Compounds 1, 4-7 modulated the MIC of EtBr by ? 2 fold against wild type clinical strains of S. aureus 1199 and S. aureus 1199B, whereas compounds 4-7 modulated the MIC of EtBr by ? 16 fold against MRSA 831. Compounds 1, 4-7 also reduced the MIC of norfloxacin by ? 8 fold against S. aureus 1199B, and 4-6 reduced the MIC of norfloxacin by ? 8 fold against MRSA 831 at half of their MICs. Inhibition of EtBr efflux by NorA-overproducing S. aureus 1199B and MRSA 831 confirmed the role of compounds 4-6 as NorA efflux pump inhibitors (EPI). Dose-dependent activity at sub-inhibitory concentration (6.25 {\ensuremath{\mu}}g/mL) suggested that compounds 4 and 5 are promising EPI compared to verapamil against 1199B and MRSA 831 strains.}
}